Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill help chinese adults with obesity shed pounds?

NCT ID NCT07790861

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether orforglipron, a once-daily oral medication, helps Chinese adults with obesity or overweight and related health conditions lose weight. Participants take either orforglipron or a placebo for about a year. Researchers measure changes in body weight, waist size, and other health markers to see if the drug is effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
orforglipron, an experimental daily oral medication
What this could lead to
If it works, orforglipron could offer a convenient daily pill to help people with obesity or overweight lose weight and reduce related health risks.
What could go wrong
This is a phase 3 trial, but results are not guaranteed. The drug may cause side effects, and benefits may vary among individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 192 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and \<30 kg/m2 or ≥24.0 kg/m2 and \<28 kg/m2, and at least 1 of the following weight-related comorbidities at screening: * hypertension * dyslipidemia * obstructive sleep apnea * Fatty liver * cardiovascular disease * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma * Have a self-reported change in body weight \>5 kg within 90 days prior to screening * Had chronic or acute pancreatitis any time prior to screening * Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jiangsu Province Hospital

    Nanjing, 210029, China

  • Jiangxi Provincial People's Hospital

    Nanchang, 330006, China

  • Jinan Central Hospital

    Jinan, 250013, China

  • Nanjing First Hospital

    Nanjing, 210006, China

  • Shanghai Sixth People's Hospital

    Shanghai, China

  • Sichuan Provincial People's Hospital

    Chengdu, 610072, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang Shi, 471003, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, 150001, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, 210011, China

  • The Second People's Hospital of Hefei

    Hefei, 230011, China

  • The first Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, 310003, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, 310014, China

  • Zhujiang Hospital

    Guangzhou, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.